Literature DB >> 28159876

What Are the Most Powerful Immunogen Design Vaccine Strategies? A Structural Biologist's Perspective.

Peter D Kwong1.   

Abstract

The ability of structure-based design to control the shape and reactivity-the atomic-level chemistry-of an immunogen argues for it being one of the "most powerful" immunogen-design strategies. But antigenic reactivity is only one of the properties required to induce a protective immune response. Here, a multidimensional approach is used to exemplify the enabling role atomic-level information can play in the development of immunogens against three viral pathogens, respiratory syncytial virus, influenza A virus, and human immunodeficiency virus (HIV), which have resisted standard approaches to vaccine development. Overall, structure-based strategies incorporating B-cell ontogenies and viral evasion mechanisms appear exceptionally powerful.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28159876      PMCID: PMC5666634          DOI: 10.1101/cshperspect.a029470

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  62 in total

1.  Bronchiolitis-associated hospitalizations among US children, 1980-1996.

Authors:  D K Shay; R C Holman; R D Newman; L L Liu; J W Stout; L J Anderson
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement.

Authors:  D A Tristram; R C Welliver; D A Hogerman; S W Hildreth; P Paradiso
Journal:  Vaccine       Date:  1994-05       Impact factor: 3.641

Review 3.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

Review 4.  Recent zoonoses caused by influenza A viruses.

Authors:  D J Alexander; I H Brown
Journal:  Rev Sci Tech       Date:  2000-04       Impact factor: 1.181

5.  Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.

Authors:  Daniel T MacLeod; Nancy M Choi; Bryan Briney; Fernando Garces; Lorena S Ver; Elise Landais; Ben Murrell; Terri Wrin; William Kilembe; Chi-Hui Liang; Alejandra Ramos; Chaoran B Bian; Lalinda Wickramasinghe; Leopold Kong; Kemal Eren; Chung-Yi Wu; Chi-Huey Wong; Sergei L Kosakovsky Pond; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

6.  Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect.

Authors:  Julie E Ledgerwood; Kathryn Zephir; Zonghui Hu; Chih-Jen Wei; Leejah Chang; Mary E Enama; Cynthia S Hendel; Sandra Sitar; Robert T Bailer; Richard A Koup; John R Mascola; Gary J Nabel; Barney S Graham
Journal:  J Infect Dis       Date:  2013-04-30       Impact factor: 5.226

7.  Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes.

Authors:  Bryan S Briney; Jordan R Willis; James E Crowe
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

8.  Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.

Authors:  Pia Dosenovic; Lotta von Boehmer; Amelia Escolano; Joseph Jardine; Natalia T Freund; Alexander D Gitlin; Andrew T McGuire; Daniel W Kulp; Thiago Oliveira; Louise Scharf; John Pietzsch; Matthew D Gray; Albert Cupo; Marit J van Gils; Kai-Hui Yao; Cassie Liu; Anna Gazumyan; Michael S Seaman; Pamela J Björkman; Rogier W Sanders; John P Moore; Leonidas Stamatatos; William R Schief; Michel C Nussenzweig
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

9.  Identification of antigen-specific B cell receptor sequences using public repertoire analysis.

Authors:  Johannes Trück; Maheshi N Ramasamy; Jacob D Galson; Richard Rance; Julian Parkhill; Gerton Lunter; Andrew J Pollard; Dominic F Kelly
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  15 in total

Review 1.  Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures.

Authors:  Gajanan Sampatrao Ghodake; Surendra Krushna Shinde; Avinash Ashok Kadam; Rijuta Ganesh Saratale; Ganesh Dattatraya Saratale; Asad Syed; Abdallah M Elgorban; Najat Marraiki; Dae-Young Kim
Journal:  Biosens Bioelectron       Date:  2021-01-04       Impact factor: 10.618

2.  The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen.

Authors:  Colin Havenar-Daughton; Anita Sarkar; Daniel W Kulp; Laura Toy; Xiaozhen Hu; Isaiah Deresa; Oleksandr Kalyuzhniy; Kirti Kaushik; Amit A Upadhyay; Sergey Menis; Elise Landais; Liwei Cao; Jolene K Diedrich; Sonu Kumar; Torben Schiffner; Samantha M Reiss; Grégory Seumois; John R Yates; James C Paulson; Steven E Bosinger; Ian A Wilson; William R Schief; Shane Crotty
Journal:  Sci Transl Med       Date:  2018-07-04       Impact factor: 17.956

3.  Functional Optimization of Broadly Neutralizing HIV-1 Antibody 10E8 by Promotion of Membrane Interactions.

Authors:  Edurne Rujas; Daniel P Leaman; Sara Insausti; Lei Ortigosa-Pascual; Lei Zhang; Michael B Zwick; José L Nieva
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

Review 4.  Antibodies against Plasmodium falciparum malaria at the molecular level.

Authors:  Jean-Philippe Julien; Hedda Wardemann
Journal:  Nat Rev Immunol       Date:  2019-08-28       Impact factor: 53.106

Review 5.  When designing vaccines, consider the starting material: the human B cell repertoire.

Authors:  Colin Havenar-Daughton; Robert K Abbott; William R Schief; Shane Crotty
Journal:  Curr Opin Immunol       Date:  2018-09-03       Impact factor: 7.486

6.  New Vaccine Design and Delivery Technologies.

Authors:  Masaru Kanekiyo; Daniel Ellis; Neil P King
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

7.  Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.

Authors:  P J Klasse; Thomas J Ketas; Christopher A Cottrell; Gabriel Ozorowski; Gargi Debnath; Diawoye Camara; Erik Francomano; Pavel Pugach; Rajesh P Ringe; Celia C LaBranche; Marit J van Gils; Christine A Bricault; Dan H Barouch; Shane Crotty; Guido Silvestri; Sudhir Kasturi; Bali Pulendran; Ian A Wilson; David C Montefiori; Rogier W Sanders; Andrew B Ward; John P Moore
Journal:  PLoS Pathog       Date:  2018-02-23       Impact factor: 6.823

Review 8.  Recent advances in veterinary applications of structural vaccinology.

Authors:  Bryan Charleston; Simon P Graham
Journal:  Curr Opin Virol       Date:  2018-03-16       Impact factor: 7.090

Review 9.  Malaria Vaccines: Recent Advances and New Horizons.

Authors:  Simon J Draper; Brandon K Sack; C Richter King; Carolyn M Nielsen; Julian C Rayner; Matthew K Higgins; Carole A Long; Robert A Seder
Journal:  Cell Host Microbe       Date:  2018-07-11       Impact factor: 21.023

Review 10.  The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens.

Authors:  Liangwei Duan; Qianqian Zheng; Hongxia Zhang; Yuna Niu; Yunwei Lou; Hui Wang
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.